/PRNewswire/ The "Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com s offering. The global.
DUBLIN (BUSINESS WIRE) The "Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering.The global biosimilars market reached a value of nearly $11,418.9 million in 2021, having grown at a compound annual growth rate (CAGR) of 34.8% since 2016. The mar.
/PRNewswire/ The "Filgrastim Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com s.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy s Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon and Aryogen Biopharma.
The global filgrastim biosimilars market is expected to decline from $511.15 million in 2019 to $445.04 million in 2020 at a compound annual growth rate (CAGR) of -12.93%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $751.96 billion in 2023 at a CAGR of 19.11%.
Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change
New York, Dec. 18, 2020 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change - https://www.reportlinker.com/p05998720/?utm source=GNW
, Biocon and Aryogen Biopharma.
The global filgrastim biosimilars market is expected to decline from $511.15 million in 2019 to $445.04 million in 2020 at a compound annual growth rate (CAGR) of -12.93%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $751.96 billion in 2023 at a CAGR of 19.11%.